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Neurodegenerative tauopathies characterized by
hyperphosphorylated tau include frontotemporal
dementia and Parkinsonism linked to chromosome
17 (FTDP-17) and Alzheimer’s disease (AD). Re-
ducing tau levels improves cognitive function in
mouse models of AD and FTDP-17, but the mecha-
nisms regulating the turnover of pathogenic tau are
unknown. We found that tau is acetylated and that
tau acetylation prevents degradation of phosphory-
lated tau (p-tau). We generated two antibodies
specific for acetylated tau and showed that tau acet-
ylation is elevated in patients at early and moderate
Braak stages of tauopathy. Histone acetyltransfer-
ase p300 was involved in tau acetylation and the
class III protein deacetylase SIRT1 in deacetylation.
Deleting SIRT1 enhanced levels of acetylated-tau
and pathogenic forms of p-tau, probably by blocking
proteasome-mediated degradation. Inhibiting p300
with a small molecule promoted tau deacetylation
and eliminated p-tau associated with tauopathy.
Modulating tau acetylation could be a new thera-
peutic strategy to reduce tau-mediated neuro-
degeneration.
INTRODUCTION
The microtubule binding protein tau (MAPT) promotes the
assembly and stabilization of microtubules (Kar et al., 2003).
Identification of tau mutations in frontotemporal dementia
patients with Parkinsonism linked to chromosome-17(FTDP-17) provides evidence that tau malfunction can trigger
neurodegeneration (Hutton et al., 1998; Spillantini et al., 1998).
In the brains of neurodegenerative tauopathies, including
Alzheimer’s disease (AD) and FTDP-17, hyperphosphorylated
tau accumulates as neurofibrillary tangles (NFTs), a diagnostic
hallmark of late-stage disease (Cairns et al., 2007; Ludolph
et al., 2009). However, the accumulation of soluble forms of
aberrantly phosphorylated tau (p-tau) may underlie tau-medi-
ated neurodegeneration by disrupting the ability of tau to bind
microtubules and promoting tau aggregation and fibrillization
(Ballatore et al., 2007). Suppression of endogenous soluble tau
or transgenic tau improves cognitive function in mouse models
of AD and FTDP-17, respectively (Roberson et al., 2007; Santa-
cruz et al., 2005). Thus, reducing tau accumulation, especially
aberrant p-tau, is a therapeutic approach for neurodegenerative
tauopathies. However, the molecular mechanisms of the accu-
mulation of hyperphosphorylated tau are unclear.
Accumulation of hyperphosphorylated tau could reflect insuf-
ficient clearance. Degradation of tau, especially p-tau, may
involve the ubiquitin-proteasome system (UPS). Soluble tau
isolated from paired helical filaments (PHF) from AD brains is
polyubiquitinated (Cripps et al., 2006). The E3 ubiquitin ligase
CHIP (carboxyl terminus of the Hsc70-interacting protein) is
involved in polyubiquitination and degradation of p-tau (Petru-
celli et al., 2004; Shimura et al., 2004). Deletion of CHIP signifi-
cantly increased p-tau levels in the brain (Dickey et al., 2006).
Ubiquitination of lysines can be precluded by lysine acetylation,
which inhibits proteasome-mediated degradation of numerous
proteins, including p53 (Ito et al., 2002), Runx (Jin et al., 2004),
and Smad7 (Gro¨nroos et al., 2002). It is unknown whether tau
is acetylated and whether tau acetylation contributes to tau
accumulation.
Lysine acetylation rivals phosphorylation in regulating diverse
cellular functions, including energy metabolism, signaling from
the plasma membrane, and cytoskeleton dynamics (ChoudharyNeuron 67, 953–966, September 23, 2010 ª2010 Elsevier Inc. 953
Neuron
Deacetylation of Tau Reduces Tauopathyet al., 2009; Kouzarides, 2000; Yang and Seto, 2008). Enzymes
that add an acetyl group to the protein are called histone acetyl-
transferase (HAT) or lysine acetyltransferase. Of four major
classes of HATs, p300/CBP (protein of 300 kDa and CREB-
binding protein) and pCAF (p300-associated and CBP-associ-
ated factor) are exclusively present in metazoans (Goodman
and Smolik, 2000). Enzymes that remove an acetyl group from
the protein are called histone deacetylases (HDACs) or lysine
deacetylases. There are three classes of HDACs. The activities
of HDACs in classes I and II (HADC1–11) depend on zinc as
a cofactor; the activities of class III HDACs (sirtuins) depend on
the relative levels of NAD+ and NADH (Haigis and Guarente,
2006; Michan and Sinclair, 2007). Of the seven members of
mammalian sirtuins (SIRT1–7), SIRT1 is the most studied and
is strongly implicated in aging-related diseases, including AD
(Gan and Mucke, 2008). SIRT1 levels are reduced in AD brains,
and the reduction correlates with the accumulation of hyper-
phosphorylated tau aggregates (Julien et al., 2009). Overex-
pressing SIRT1 protects against neuronal loss in the inducible
p25 transgenic mouse, a model of AD and tauopathy (Kim
et al., 2007). It is unclear how SIRT1 protects against tau-medi-
ated neurodegeneration.
In the current study, we investigated tau acetylation in primary
neurons, tauopathy mouse models, and AD brains by generating
two specific antibodies against acetylated-tau (ac-tau). Using
gene-silencing and pharmacological approaches, we show
that p300 acetylates and SIRT1 deacetylates tau. Our study
also provided evidence that SIRT1 deficiency leads to hyperace-
tylation of tau and accumulation of p-tau. In contrast, promoting
tau deacetylation eliminates p-tau.
RESULTS
Tau Is Acetylated in Vitro and in Vivo
To demonstrate that tau is acetylated, we incubated recombi-
nant tau with recombinant acetyltransferase p300 or pCAF
(p300/CBP-associated factor) with 14C-acetyl-coenzyme A.
Incubation with p300, not pCAF, led to tau acetylation, whereas
both p300 and pCAF were active in transferring acetyl groups to
histones as expected (Figure 1A). Matrix-assisted laser desorp-
tion/ionization-time of flight (MALDI-TOF) spectrometry identi-
fied multiple lysines that were acetylated by p300 in vitro. A total
of 23 putatively acetylated lysines were detected out of 383 resi-
dues (86.8% coverage; Table S1 available online) throughout
the tau sequence (2N4R, 441 amino acids). A few putative acet-
ylated lysines were in the N- and C-terminal regions; 13 were in
microtubule-binding domains (Figure 1B and Table S1). Putative
acetylated N-terminal lysines (e.g., lysines 163, 174, and 180)
appeared to be acetylated in all MS analyses. Those in themicro-
tubule-binding domains appeared to be acetylated in a subset of
MS analyses, suggesting variable acetylation at these sites
in vitro (Table S1).
To examine tau acetylation in vivo, we generated a polyclonal
antibody (anti-ac-tau, Ab708) with a synthetic tau peptide (amino
acids 160–182 for 2N4R tau isoform) containing acetylated
lysines at positions 163 and 174 and 180 (see Figure S1 for MS
spectra). A control antibody was generated (anti-tau, Ab707)
with the same peptide with nonacetylated lysines. To test the954 Neuron 67, 953–966, September 23, 2010 ª2010 Elsevier Inc.specificity of Ab708 against ac-tau, we incubated recombinant
human tau (441; 2N4R isoform) with glutathione S-transferase
(GST) alone or GST-p300. Immunoblotting with Ab708 detected
strong tau signals after incubation with GST-p300, but not with
GST alone (Figure 1C). In contrast, Ab707 or Tau 5 antibody
detected similar levels of total tau (t-tau) with either GST or
GST-p300 (Figure 1C). Thus, Ab708 specifically recognizes tau
acetylated by p300 under cell-free conditions. In HEK293T cells
transfected with tau, overexpression of p300 markedly elevated
the levels of ac-tau detected with Ab708 while the increase in the
levels of t-tau was modest, suggesting that Ab708 preferentially
recognizes p300-induced ac-tau in cultured cells (Figure 1D).
Mutation of lysines 163, 174, and 180 (Tau3KR) reduced ac-tau
levels relative to t-tau levels in HEK293T cells (Figure 1E).
A smaller yet still significant reduction was also observed when
two lysines were mutated in Tau2KR(K174R/K180R) (Figure 1E).
These findings suggest that Ab708 recognizes human tau
acetylated at positions 163, 174, or 180 and possibly other acet-
ylated lysines on tau, but not nonacetylated tau.
To detect ac-tau in vivo, we performed Western blots with
brain lysates from transgenic mice expressing human tau
cDNA (1N4R) with P301S mutation (PS19) (Yoshiyama et al.,
2007) or from transgenic mice expressing the entire human
wild-type MAPT (hT-PAC-N) with 0N3R and 0N4R as the two
predominant tau isoforms (McMillan et al., 2008). Human and
mouse tau differ at three positions in the region used to generate
Ab708 and Ab707 (Figure S2). Ab708 detected specific signals in
lysates from PS19 and hT-PAC-N mice, but not those from
nontransgenic (NTG) littermates (Figure 1F). These findings
suggest that Ab708 recognizes various isoforms of human
ac-tau, but not mouse ac-tau. The control antibody Ab707,
which recognizes human t-tau, does not recognize mouse tau
either. Endogenous tau in NTG mice was detected with Tau 5
antibody (Figure 1F).
Rat tau is more similar to human tau than mouse tau in the
region used to generate Ab708 (Figure S2). Ab708 detected
endogenous ac-tau in rat primary cortical neurons (Figure 1G).
Levels of ac-tau/t-tau gradually increased as neurons matured
from 5–12 days in vitro (DIV), suggesting that tau acetylation is
regulated developmentally (Figure 1G). However, the isoforms
of rat tau detected by Ab708 remain to be defined.
Acetylation of Tau by p300 Acetyltransferase
To determine the role of endogenous p300 or pCAF in tau acet-
ylation, we transfected HEK293T cells expressing human tau
cDNA (2N4R) with siRNAs targeting p300 or pCAF (Figure 2A)
and assessed the effects on ac-tau or t-tau. Reducing p300
significantly lowered levels of ac-tau, but not t-tau (Figures 2B
and 2C). In contrast, inhibiting pCAF had no effects (Figures 2B
and 2C). These findings are consistent with the results of
in vitro studies (Figure 1A). Next, we treated primary neurons
with C646, a pyrazolone-containing small-molecule inhibitor of
p300 (Bowers et al., 2010). Under cell-free conditions, C646 at
10 mM inhibits p300 in a highly selective manner (86% inhibition
versus < 10% for the six other acetyltransferases) (Bowers et al.,
2010). Inhibition of p300 with C646 (20 mM) drastically reduced
levels of ac-tau in primary neurons within 8 hr. The levels of
t-tau remained unchanged (Figure 2D). p300 is a transcriptional
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Figure 1. Tau Is Acetylated In Vitro and In Vivo
(A) Acetylation of h-tau (2N4R) by p300 but not pCAF under cell-free conditions, as shown by autoradiography.
(B) MALDI-TOF spectrometry identified ac-lysines on h-tau by p300 in vitro. Formatting is used as follows: red, lysines (K) with acetyl group; underlined, sequence
covered by MS analysis; blue box, microtubule-binding domains. See Table S1 for full list and Figure S1 for MS-MS spectra.
(C–E) Ab708 specifically recognizes ac-tau. As shown in (C), Ab708 only recognized recombinant tau acetylated by GST-p300, not nonacetylated tau with GST
alone. Similar levels of t-tau were detected with Ab707 and Tau 5 antibody. (D) shows overexpressing p300 markedly enhanced ac-tau, detected with Ab708, in
HEK293T cells. Levels of t-tau, detected with Tau 5, were similar with or without p300. Blots are representative of >5 experiments. As shown in (E), putatively
acetylated lysine sites recognized by Ab708. Ac-tau/t-tau levels in HEK293T cells expressing wild-type tau were set as 1. n = 4. *p = 0.012; **p = 0.003;
***p = 0.0003 (one-way ANOVA with Tukey-Kramer posthoc analysis).
(F) Ab708 recognizes human ac-tau in brains of PS19 or hT-PAC-N transgenic mice, not in NTG littermates. Human t-tau was detected with Ab707 antibody;
human and mouse t-tau was detected with Tau 5 antibody. See Figure S2 for the sequence similarity among human, mouse, and rat tau.
(G) Levels of Ab708-positive ac-tau were elevated in primary rat neurons as they matured in culture (DIV = 5–12). n = 2–7 from 2–3 independent experiments.
***p < 0.001 (DIV5 versus DIV8 or DIV12); **p < 0.01 (DIV5 versus DIV9–11). Values represent means ± SEM (E and G).
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Deacetylation of Tau Reduces Tauopathycoactivator (Goodman and Smolik, 2000). However, C646 treat-
ment for 8 hr did not suppress tau transcripts as quantified with
real-time RT-PCR (data not shown). Thus short-term (8 h) inhibi-
tion of p300 deacetylates tau without affecting t-tau levels.
Extended treatment with C646 for 20 hr lowered the levels of
ac-tau relative to the t-tau (ac-tau/t-tau), but also those of t-tau
(Figure 2E).Deacetylation of Tau by SIRT1 in Cultures
To investigate the enzymes that deacetylate tau, we transfected
an expression vector encoding FLAG-tagged SIRT1, SIRT2,
HDAC5, or HDAC6 into HEK293T cells expressing human tau.
All HDACs were expressed at high levels (Figure 3A). Although
expressed at lower levels than SIRT1 and SIRT2, HDAC6 elimi-
nated tubulin acetylation (Hubbert et al., 2002), suggestingNeuron 67, 953–966, September 23, 2010 ª2010 Elsevier Inc. 955
ac-tau
t-tau
GAPDH
   C646 
(p300 inhibitor) 0
0.2
0.4
0.6
0.8
1.0
1.2
   C646Control
50 
50 
37 
 
N
or
m
al
iz
ed
 a
c-
ta
u/
t-t
au
C
8 h Treatment 20 h Treatment
ac-tau
t-tau
GAPDH37 
50 
50 
   C37
(control)    C646 (p300 inhibitor)
   C37
(control)
D
**
0
0.2
0.4
0.6
0.8
1.0
B
 
N
or
m
al
iz
ed
 
ac
-ta
u/
 o
r t
-ta
u/
G
AP
DH
t-tau ac-tau
0
0.2
0.4
0.6
0.8
1.0
 
N
or
m
al
iz
ed
 
p3
00
 o
r p
CA
F/
G
AP
DH
***
p300con pCAFsiRNA: consiRNA:
1.2
p300 pCAF
***
E
ac-tau
t-tau
p300
GAPDH
si-p300si-con
Tau-WT
75 
75 
300 
A
0
0.50
0.75
1.00
1.25
0.25
ac-tau
t-tau
pCAF
GAPDH
si-pCAFsi-con
Tau-WT
75 
75 
37 
37 37 
   C646Control
 
N
or
m
al
iz
ed
 a
c-
ta
u/
t-t
au
Figure 2. Tau Is Acetylated by p300 Acetyltransferase
(A–C) Inhibiting p300, not pCAF, reduced ac-tau in HEK293T cells. (A) shows inhibition of p300 or pCAF expression by siRNA transfections. Levels of
p300/GAPDH or pCAF/GAPDH in control siRNA-transfected cells were set as 1. ***p = 0.0006 (p300 versus control) or p < 0.0001 (pCAF versus control).
In (B), representative western blots (from three experiments) showing levels of p300 or pCAF, ac-tau, t-tau, and GAPDH in cells transfected with control siRNA
(si-con) or siRNA targeting p300 or pCAF are shown. As shown in (C), inhibition of p300, not pCAF, reduced ac-tau levels. Levels of ac-tau/GAPDH or t-tau/
GAPDH in control siRNA-transfected cells were set as 1. n = 5–6. **p = 0.008 (paired t test).
(D) Inhibiting p300 acutely with C646 (20 mM for 8 hr) eliminated ac-tau without affecting t-tau levels in primary rat cortical neurons. Shown on the left is repre-
sentative western blotting from three experiments. As shown on the right, Ac-tau/t-tau levels in vehicle-treated cells were set as 1. n = 3. ***p = 0.0001 (unpaired
t test).
(E) Extended treatment with C646 (20 mM for 20 h) lowered ac-tau and t-tau in primary cortical neuron. Blots are representative of two experiments. Values are
means ± SEM (A and C–E).
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Deacetylation of Tau Reduces Tauopathysufficient expression (Figure 3B). Overexpression of SIRT1
reduced levels of Ab708-positive ac-tau. SIRT2 and HDAC6
overexpression also lowered ac-tau, although to lesser extents
(Figures 3B and 3C). Levels of t-tau were also reduced in cells
overexpressing SIRT1 and HDAC6. Nevertheless, the ac-tau/
t-tau ratio was significantly reduced by SIRT1 overexpression
(Figure 3D). The modest reduction in ac-tau/t-tau induced by
HDAC6 or SIRT2 overexpression was not statistically significant
(Figure 3D).
To examine the effects of endogenous HDACs on ac-tau, we
inhibited expression of SIRT1, SIRT2, or HDAC6 with siRNAs
(Figure 3E). Relative to control siRNA, target siRNAs significantly
reduced levels of SIRT1, SIRT2, and HDAC6. Despite modest
inhibition, HDAC6 increased ac-tubulin levels (Figure 3F).
However, only inhibition of SIRT1 increased ac-tau levels, sug-
gesting the involvement of endogenous SIRT1 in deacetylating
tau (Figure 3G). Consistent with the observation that SIRT1 over-
expression reduced t-tau, SIRT1 inhibition led to a trend of
increase in t-tau (Figure 3G). Nevertheless, inhibition of SIRT1,
not SIRT2 or HDAC6, significantly elevated levels of ac-tau rela-
tive to t-tau (ac-tau/t-tau) (Figure 3H). These results provided
direct support that SIRT1 is involved in tau deacetylation. Our
findings so far do not support a prominent role of SIRT2 or
HDAC6, which both deacetylate tubulin (Hubbert et al., 2002;956 Neuron 67, 953–966, September 23, 2010 ª2010 Elsevier Inc.North et al., 2003), in tau deacetylation. However, their involve-
ment cannot be ruled out given that only partial silencing of
SIRT2 or HDAC6 was achieved with siRNA transfections.
To further investigate the role of SIRT1 in tau deacetylation, we
transfected low-passage mouse embryonic fibroblasts (MEF)
with (SIRT1+/+) or without SIRT1 (SIRT1/) with human tau
cDNA (Figure S3). Deleting SIRT1 significantly raised ac-tau
levels. The increase in t-tau did not reach statistical significance,
suggesting SIRT1 deacetylates tau in MEFs. In HEK293T cells,
when lysines 163, 174, and 180 were mutated to arginines
(Tau3KR), levels of ac-tau were significantly reduced
(Figure 3I). SIRT1 overexpression reduced ac-tau in TauWT cells,
but the reduction was much attenuated in Tau3KR cells
(Figure 3I). These results implicate SIRT1 in deacetylating lysines
163, 174, and 180. However, SIRT1 reduced ac-tau to lower
levels in Tau3KR cells than in TauWT cells, indicating that
SIRT1 could deacetylate additional lysine residues besides
those at positions 163, 174, and 180 (Figure 3I).
SIRT1 Reduces Tau Acetylation in Primary Neurons
and In Vivo
In primary neurons, ac-tau/t-tau increased as the neurons
matured (Figure 1G), but levels of full-length SIRT1 decreased
(Figure 4A). Consistent with the notion that SIRT1 deactylates
Neuron
Deacetylation of Tau Reduces Tauopathytau, levels of SIRT1 negatively correlated with levels of ac-tau/
t-tau in primary neurons during development (Figure 4B). To
investigate whether SIRT1 negatively regulates tau acetylation
in neurons, we deleted SIRT1 in neurons by infecting neurons
from SIRT1 conditional knockout mice (SIRT1F/F) (Chua et al.,
2005) with a lentiviral vector expressing cre recombinase
(Lenti-cre) (Figure 4C). Controls were infected with an empty
vector (Lenti-con). SIRT1F/F neurons were also infected with
a lentiviral vector expressing human tau. Deleting SIRT1 signifi-
cantly elevated levels of acetylated human tau relative to t-tau
(Figure 4C), indicating that SIRT1 deacetylates tau in neurons.
To examine the effects of SIRT1 deletion on the acetylation of
mouse tau in vivo,wedevelopedanother ac-tau-specificantibody
targeting the microtubule-binding region (264–287), which is
100% conserved between mouse and human (Figure 4D).
Recombinant tau was incubated with p300 to induce acetylation.
LikeAb708, antibody 9AB recognized recombinant tau acetylated
by GST-p300, but not tau incubated with GST alone, suggesting
that 9AB does not cross-react with non-ac-tau. In HEK293T cells,
overexpression of p300 markedly elevated levels of ac-tau de-
tected with 9AB, but only modestly those of t-tau. Thus, 9AB
also preferentially recognizes p300-induced ac-tau in cultured
cells (Figure 4E). In mouse brains, 9AB detected low levels of
ac-tau, which was absent in tau/ mice. To delete SIRT1, we
crossedSIRT1+/miceonanoutbredbackground,whichpartially
rescued the embryonic lethality of SIRT1 null mice on the inbred
background (Cheng et al., 2003). Deleting SIRT1 significantly
enhanced levels of ac-tau in the brain, providing direct evidence
that SIRT1 deacetylates tau in vivo (Figure 4F).
SIRT1 Interacts with Tau Directly
Although mainly localized in the nucleus, SIRT1 can be shuttled
to the cytoplasm (Hisahara et al., 2008; Tanno et al., 2007).
To determine whether SIRT1 directly deacetylates tau, we per-
formed in vitro deacetylation assays. Recombinant tau acety-
lated by p300 was incubated with SIRT1 immunoprecipitated
from SIRT1-overexpressing HEK293T cells. Ac-tau/t-tau levels
were significantly lower in the presence of immunoprecipitated
SIRT1 (Figure 5A). To confirm that SIRT1 interacts with tau
directly in vivo, we performed GST pull-down assays. Bead-
bound GST-tau, not GST alone, interacted with FLAG-SIRT1 ex-
pressed in HEK293T cells or endogenous SIRT1 in nontrans-
fected cells (Figure 5B). Moreover, in coimmunoprecipitation
assays, after immunoprecipitation with an anti-FLAG antibody,
endogenous SIRT1 was detected with an anti-SIRT1 antibody,
and tau was detected with a pan-tau antibody (Tau 5) in
HEK293T cells expressing FLAG-tagged tau (Figure 5C).
SIRT1 Deficiency Increases Tau Acetylation
and Suppresses Degradation of p-Tau
As a class III lysine deacetylase, SIRT1 supports and promotes
longevity in diverse organisms. Besides regulating endocrine
and behavioral responses to caloric restriction (Cohen et al.,
2009), SIRT1 has been strongly implicated in neurodegenerative
diseases (reviewed in Gan and Mucke, 2008). In AD brains,
SIRT1 levels are significantly reduced, and the reduction
appears to correlate with tau accumulation and aggregation
(Julien et al., 2009). Thus, deficient SIRT1 activity may contributeto tauopathy. In primary neurons, inhibiting SIRT1 with a specific
inhibitor EX527 (Napper et al., 2005) markedly increased ac-tau,
AT8-positive p-tau, as well as t-tau (Figure 6A). Levels of ac-tau
or p-tau relative to t-tau were significantly increased with EX527
treatments (Figure 6A). Thus, the increase in ac-tau induced by
SIRT1 deficiency is accompanied by accumulation of patho-
genic p-tau in primary neurons. In mouse brains, deleting
SIRT1, which elevated ac-tau, also increased AT8-positive
p-tau (Figure 6B).
How might elevated tau acetylation lead to higher levels of
p-tau? Acetylation of lysines can preclude its ubiquitination
and stabilize proteins that are normally degraded by the UPS,
including p53 (Ito et al., 2002), Runx3 (Jin et al., 2004), b-catenin
(Ge et al., 2009), and other regulatory factors (Caron et al., 2005).
Because tau is ubiquitinated and the degradation of tau,
especially p-tau, involves the proteasome-mediated pathway
(Petrucelli et al., 2004; Tan et al., 2008), we hypothesized that
acetylation precludes tau ubiquitination and suppresses its
degradation.
To test this hypothesis, we assessed the involvement of acet-
ylated lysines in regulating protein turnover. We compared the
turnover rates of human wild-type tau (hTauwt) and human
tau3KR (hTau3KR). Primary cortical neurons were infected with
Lenti-hTauwt and Lenti-hTau3KR and treated with cyclohexi-
mide (CHX) (Figure 6C). Infection of Lenti-hTau3KR resulted in
much weaker Ab708-positive signal than that of Lenti-hTauwt,
providing further support that Ab708 recognizes acetylation
of lysines 163, 174, and 180. Mutating these three lysines to
arginines significantly increased the half-life of tau, possibly
by permanently blocking ubiquitination at the three sites
(Figure 6D). These results support the notion that the acetylated
lysines can be ubiquitinated.
To directly test whether enhancing acetylation can block ubiq-
uitination, we transfected HEK293T cells with expression plas-
mids encoding tau and hemagglutinin (HA)-tagged ubiquitin
and then treated them with EX527 to inhibit SIRT1 and with
MG132 to block the proteasome-mediated degradation. Ubiqui-
tinated tau was immunoprecipitated with an anti-FLAG antibody
and detected with an anti-HA antibody. EX527 prevented polyu-
biquitination of tau in a dose-dependent manner, indicating that
tau ubiquitination is suppressed by enhanced acetylation
(Figure 6E). EX527 also elevated ac-tau levels as expected
(Figure 6F). In contrast, SIRT1-mediated deacetylation appears
to enhance tau ubiquitination. Treatment with resveratrol, which
may be indirectly involved in activating SIRT1, significantly
increased tau ubiquitination in cells transfected with wild-type
SIRT1, but not those with H363Y mutant (Figure S4).
We thendirectlyexaminedwhether enhancingacetylationof tau
slows the turnover of endogenous tau. Primary neurons were
treated with EX527 to enhance tau acetylation and with CHX to
inhibit translation of new proteins. Endogenous rat tau in primary
neurons had a half-life of 5 hr. Inhibiting SIRT1 with EX527
slowed tau turnover and increased the half-life of t-tau in
a dose-dependent manner (Figures 6G and 6H). Consistent with
this notion, ac-tau appears to be degraded slower than that of
t-tau. In primary neurons, CHXmarkedly reduced t-tau levels after
5 hr, whereas ac-tau levels were only slightly reduced after 8 hr
(Figure S5). Moreover, inhibition of SIRT1 with 10 mM of EX527Neuron 67, 953–966, September 23, 2010 ª2010 Elsevier Inc. 957
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Figure 3. SIRT1 Deacetylates Tau in Culture
(A–D) SIRT1 overexpression lowered ac-tau levels in HEK293T cells.
(A) Western blot showing expression of FLAG-tagged SIRT1, SIRT2, HDAC5, or HDAC6 with an anti-FLAG antibody. Blots are representative of 2–3 experiments.
(B) Western blot showing levels of ac-tau, t-tau, tubulin, and ac-tubulin in cells overexpressing SIRT1, SIRT2, HDAC5, or HDAC6. Blots are representative of two
to three experiments.
(C) Overexpression of SIRT1, SIRT2, or HDAC6 significantly reduced levels of ac-tau/GAPDH. Levels of t-tau were also reduced by SIRT1 or HDAC6 overexpres-
sion. n = 9–18 from 6–10 independent experiments. ***p < 0.001 (Mock versus SIRT1 or Mock versus HDAC6); **p < 0.01 (Mock versus SIRT2) (two-way ANOVA
and Bonferroni post hoc test).
(D) Overexpression of SIRT1 significantly reduced ac-tau/t-tau. n = 9–18 from 6–10 independent experiments, ***p < 0.001 (Mock versus SIRT1) (one-way ANOVA
and Tukey-Kramer post hoc test).
(E–H) Inhibition of SIRT1 elevated ac-tau in HEK293T cells.
(E) Inhibition of SIRT1, SIRT2, or HDAC6 expression mediated by siRNA transfections. n = 4–6 from 2–3 experiments. **p = 0.0015; ***p = 0.0001 (SIRT2 versus
control) or p = 0.001 (HDAC6 versus control) (paired t test).
(F) Western blot showing levels of ac-tau, t-tau, tubulin, and ac-tubulin in cells transfected with control siRNA or siRNA targeting SIRT1, SIRT2, or HDAC6. Blots
are representative of two to three experiments.
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Figure 4. SIRT1 Reduces Tau Acetylation in
Neurons and In Vivo
(A) Western blot showing expression of SIRT1 in
primary cortical neurons during maturation in
culture (DIV5–11). Blots are representative of two
to three independent cultures.
(B) Levels of endogenous ac-tau relative to t-tau
correlated negatively with levels of SIRT1 in
primary rat neuronal cultures (DIV5–9). Levels of
SIRT1 or ac-tau/t-tau at DIV = 5 were set as 1.
n = 20 independent measurements. p = 0.0007,
Pearson correlation coefficient r2 = 0.4791.
(C) Deleting SIRT1 in neurons elevated levels of ac-
tau relative to t-tau.Neurons cultured fromSIRT1F/F
mice were infected with control virus or virus
expressing cre recombinase (Lenti-cre). Both
cultures were also infected with a lentiviral vector
expressing h-tau. n = 8. **p= 0.001 (unpaired t test).
(D) Acetyl-specific antibody (9AB) recognized tau
acetylated by GST-p300, but not non-ac-tau.
Also shown is the sequence of the antigen used
to generate 9AB.
(E) Overexpressing p300 enhanced 9AB-positive
ac-tau in HEK293T cells. Levels of t-tau, detected
with Tau 5, were similar with or without p300 over-
expression. Blots are representative of three inde-
pendent experiments.
(F) Deletion of SIRT1 elevated ac-tau relative to
t-tau in the brain. Left: Representative Western
blots showing levels of ac-tau, t-tau, and GAPDH.
Right: Levels of ac-tau/t-tau in SIRT1+/+, SIRT1+/,
and SIRT1/ brains. n = 3–6 mice/genotype.
*p = 0.02 (SIRT1+/ versus SIRT1/) (one-way
ANOVA and Tukey-Kramer posthoc test). Values
are means ± SEM (C, F).
Neuron
Deacetylation of Tau Reduces Tauopathyblocked the turnover of ac-tau, leading its accumulation (Figures
6I and 6J). Higher dose of EX527 (50 mM) resulted in more
pronounced accumulation of ac-tau (Figure 6I). Treatment with
EX527 also blocked the degradation of AT8-positive p-tau in
a dose-dependent manner (Figure 6K).
Elevation of Tau Acetylation in Pathological Conditions
Because degradation of tau was slowed by its acetylation,
we hypothesized that acetylation is a critical early event that(G and H) Inhibition of SIRT1, significantly elevated levels of ac-tau/GAPDH (G) or ac-tau/t-tau (H). n = 4–6 from
deacetylase/GAPDH (E), ac-tau or t-tau/GAPDH (G), and ac-tau/t-tau (H) in control siRNA-transfected cells w
levels of ac-tau in MEFs with (SIRT1+/+) or without SIRT1 (SIRT1/).
(I) Deacetylation of Tau3KR by SIRT1. On the left is a representative Western blot showing levels of ac-tau, t-ta
the right, Ac-tau/t-tau levels in mock-transfected cells expressing wild-type tau were set as 1. n = 10–20 from 4
significant (one-way ANOVA and Tukey-Kramer post-hoc analysis). Values are means ± SEM (C–E and G–I)
Neuron 67, 953–966, Secontributes to accumulation of p-tau
that is normally degraded via the protea-
some-mediated pathway (Petrucelli
et al., 2004; Tan et al., 2008). In primary
neurons, treatment with low levels of
amyloid b (Ab) oligomers, a key pathogen
in AD, increased levels of ac-tau in
a dose-dependent manner (Figure 7A).Higher levels of ac-tau were observed in primary neurons ex-
pressing human tau carrying FTD-linked mutation (hTauP301L)
than those expressing similar levels of hTauwt (Figure 7B). These
findings suggest that tau acetylation is elevated by stress, such
as Ab accumulation, or FTD-linked mutations.
We next examined tau acetylation in the frontal cortex of
patients with different degrees of tau pathology (Braak and
Braak, 1991) (Table S2). Patients at Braak stages 1–2 or 3–4
had significantly higher levels of ac-tau in the soluble fraction2–3 experiments. *p < 0.05 (paired t test). Levels of
ere set as 1. Also see Figure S3 for comparison of
u, FLAG-tagged SIRT1, and GAPDH. As shown on
–10 independent experiments. ***p < 0.001; ns, not
.
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Figure 5. SIRT1 Interacts with Tau
(A) SIRT1 directly deacetylated ac-tau in vitro.
Ac-tau/t-tau levels in the absence of immunopre-
cipitated SIRT1 were set as 1. Ac-tau was de-
tected with Ab708 antibody. n = 5 from two exper-
iments. **p = 0.0063 (unpaired t test).
(B) GST pull-down assays. GST-tau protein
(lanes 7–9) or GST alone (lanes 4–6) was incubated
with lysates of cells transfected with FLAG-tagged
SIRT1 or of nontransfected cells. Lanes 1, 4, and 7:
0.1% Triton X-100; lanes 2, 5, and 8: 0.5% Triton
X-100; lanes 3, 6, and 9: 0.5% NP-40. Data shown
are representative of two experiments. The lower
band is likely to represent the cleavage product of
SIRT1 observed previously (Ohsawa and Miura,
2006).
(C) Coimmunoprecipitation assays. HEK293T cells were transfected with a plasmid encoding FLAG-tagged human tau. Cell lysates were collected 24 hr later,
immunoprecipitated with an anti-FLAG antibody, and immunoblotted with Tau 5 or an anti-SIRT1 antibody. Lanes 1–2: input; lane 3: no primary antibody; lane 4:
anti-FLAG antibody. Values are means ± SEM (A).
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Ab708 can recognize various human tau isoforms in transgenic
mice overexpressing human tau (Figure 1D). However, unlike
Tau 5, which detects all isoforms, Ab708 appears to detect
some isoforms preferentially in AD brains (Figure 7C). Hyper-
phosphorylated tau detected with PHF-1 (Figure 7C) or AT8
(data not shown) was observed only in patients at stages 5–6,
consistent with lack of significant NFTs in the frontal cortex of
patients at earlier Braak stages (Braak and Braak, 1991). Thus,
our findings support the notion that enhanced tau acetylation
precedes hyperphosphorylation of tau and NFT formation.
However, in patients at Braak stages 5–6, especially those at
stage 6, with NFTs in the frontal cortex, levels of ac-tau were
slightly lower than patients at mild to moderate stages. This
end-stage reduction might be explained by severe loss of
neurons, or sequestration of ac-tau in the NFTs, thus remaining
in the insoluble fractions of the lysates.
Reducing Tau Acetylation Eliminates p-Tau Induced by
FTD-linked Mutation
To test the hypothesis that tau acetylation contributes to p-tau
accumulation, we determined whether inhibiting tau acetylation
eliminates p-tau and protects against tauopathy. Inhibiting
p300 in primary neuronswith the small molecule C646 eliminated
ac-tau without affecting t-tau levels (Figure 8A). Strikingly, path-
ogenic tau phosphorylated at serine 202, detected with AT8 anti-
body, was also abolished within 2 hr treatment with C646. Its
inactive analog C37 had no effects (Figure 8B). These results
suggest that deacetylation preferentially enhances degradation
of p-tau, consistent with the observation that p-tau species are
selectively degraded via the UPS pathway (Dickey et al., 2007;
Dickey et al., 2006). In primary neurons expressing hTauP301L,
a cellularmodel of tauopathy, AT8-positive p-tauwas also dimin-
ished by C646 treatment (Figure 8C). Reducing tau improves
cognitive function in mouse models of AD and FTDP-17 (Rober-
son et al., 2007; Santacruz et al., 2005) and protects against ex-
citotoxicity (Roberson et al., 2007). Our results implicate modu-
lating lysine acetylation as a new therapeutic strategy to
reduce levels of tau, especially pathogenic forms of p-tau, in
neurodegenerative tauopathies.960 Neuron 67, 953–966, September 23, 2010 ª2010 Elsevier Inc.DISCUSSION
Using two antibodies specific for ac-tau that we developed, we
found that tau is acetylated and that acetylation of tau contributes
to the accumulation of p-tau. In primary neurons, tau acetylation
was elevated by an FTDP-17-linkedmutation and by low levels of
oligomeric Ab. Tau acetylation was enhanced in patients at early
and moderate Braak stages of tau pathology, before NFTs form.
Moreover, we demonstrated that SIRT1 deacetylates tau and
that acetyltransferase p300 mediates its acetylation. SIRT1 defi-
ciency elevated ac-tau in vivo. Inhibition of SIRT1 blocked tau
polyubiquitination and tau turnover, resulting in p-tau accumula-
tion. In contrast, deacetylating tau by inhibiting p300with a highly
specific small-molecule inhibitor effectively eliminated p-tau.
Our ac-tau-specific antibodies Ab708 or 9AB did not recog-
nize nonacetylated recombinant tau, allowing us to specifically
detect ac-tau in vivo. The mutagenesis study showed that
Ab708 recognizes the acetylated lysines at positions 163, 174,
and 180, and possibly other acetylated lysines. Mass spectrom-
etry detected p300-induced tau acetylation at 23 lysines.
However, p300 probably acetylates other lysines in the 13% of
the tau sequence we did not analyze. Importantly, the sites acet-
ylated in vivo probably would differ from those mapped under
cell-free conditions. In addition, depending on neuronal
subtypes and cellular conditions, different sets of lysines could
be acetylated. Systematic mass spectrometry will be needed
to map the acetylation sites of tau under different pathophysio-
logical conditions.
p300 induced tau acetylation both in vitro and in vivo. Exactly
how p300 acetylates tau in vivo remains to be determined.
Although p300 is mainly a nuclear protein, it can be cytosolic,
acting as an E4 ubiquitin ligase for p53 (Shi et al., 2009). Small
amount of tau may also be present in the nucleus in some cell
types (Wang et al., 1993). It is thus possible that p300 acetylates
tau directly. However, p300 could also induce tau acetylation
indirectly by unknown mechanisms. Inhibition of p300 with
siRNA or the small molecule C646 reduced ac-tau levels signifi-
cantly. C646 induced a much stronger decetylation effect than
p300 siRNA, perhaps because C646may also inhibit CBP, which
shares 90%homology with p300 in the acetyltransferase domain
Neuron
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p300, inhibition of both by C646 is likely to result in much
stronger effects than inhibition of p300 only with siRNA.
Our study suggests that SIRT1 interacts with tau in vivo and
directly deacetylates tau under cell-free conditions. Inhibition of
SIRT1 with siRNA or the small molecule EX527 increased tau
acetylation, and deleting SIRT1 elevated ac-tau in mouse brains.
However,whetherSIRT1directly deacetylates tau in vivo remains
to be established. SIRT1 shuttles between the nucleus and
cytosol, and its subcellular localization is regulated by patho-
physiological stimuli. SIRT1 is localized in the cytoplasm of
embryonic and adult neural precursor cells, but transiently trans-
located in thenucleus in response todifferentiation stimuli, result-
ing in reduction of cytosolic SIRT1 activities during differentiation
(Hisahara et al., 2008). We found that levels of ac-tau were
increased in primary neurons during maturation and correlated
negatively with SIRT1 levels. These findings support the model
that increased tau acetylation during neural maturation could
be mediated by a reduction in cytosolic SIRT1 activity. The
subcellular localization of SIRT1 is also modulated by stress
and apoptosis (Greiss et al., 2008; Jin et al., 2007), providing
potential mechanisms by which SIRT1 regulates tau acetylation
and tauopathy during neuronal injury.
In human brains, elevated tau acetylation preceded the accu-
mulation of NFTs, supporting the model that tau acetylation is an
early event in tau-mediated neurodegeneration (Figure 8D). Our
findings also suggest that tau acetylation is increased by stress
due to Ab accumulation or by mutations associated with tauop-
athy. However, the exact mechanisms underlying increased tau
acetylation are undefined. Some likely mechanisms include
deficiency in SIRT1 levels or SIRT1 activities in the cytosol,
enhanced p300/CBP levels or p300/CBP activity, or alterations
in tau conformation that block the access and/or binding to
deacetylases or enhance the access and/or binding to acetyl-
transferases. These mechanisms are not mutually exclusive.
Inhibition of p300 diminished ac-tau in primary neurons express-
ing TauP301L, consistent with the notion that P301L-induced
hyperacetylation requires active p300. In AD brains, SIRT1 levels
are reduced, and this reduction correlates with the amount of tau
aggregates (Julien et al., 2009), consistent with a role of SIRT1
deficiency in Ab-induced tau hyperacetylation. SIRT1 was
found to reduce Ab generation by activating transcription of
a gene encoding a-secretase (Donmez et al., 2010). SIRT1
deficiency could also exacerbate the accumulation of Ab,
which could increase tau acetylation and tau phosphorylation
even further. Other stress pathways induced during neuronal
injury may also contribute to tau hyperacetylation and hyper-
phosphorylation.
Little is known how acetylation affects the functions of tau. We
focused on the role of acetylation in ubiquitin-dependent degra-
dation and effects on p-tau. However, acetylation of tau is likely
to play other important roles in the development of tau-mediated
neuropathology. We identified at least 13 putatively acetylated
lysines in the microtubule-binding domains, within which the
positively charged proline-rich regions are tightly bound to nega-
tively charged microtubule surface (Amos, 2004; Kar et al.,
2003). Because acetylation neutralizes charges in the microtu-
bule-binding domain, aberrant acetylation might interfere withthe binding of tau to microtubule, leading to tau dysfunction
(Figure 8D). These residues appear to be variably acetylated by
p300 in vitro, consistent with a dynamic acetylation process
that is amenable to modulation in vivo.
The crosstalk of tau acetylation with tau ubiquitination or phos-
phorylation may have implications for tau-mediated neurode-
generation (Figure 8D). Our findings suggest that tau acetylation
directly contributes to accumulation of p-tau, a hallmark of tau-
opathy. Besides affecting p-tau turnover, tau acetylation may
also modulate the activities of kinases involved in tau phosphor-
ylation (Figure 8D). How kinase activities are modulated by tau
acetylation is unknown. Regardless of the exact mechanisms,
SIRT1 deficiency, high Ab levels, or FTDP-17-linked mutations
could lead to hyperacetylation of lysines on p-tau, preventing it
from being ubiquitinated and degraded via the UPS pathway.
In contrast, inhibition of p300 diminished ac-tau and effectively
eliminated p-tau, suggesting that interfering with tau acetylation
may be a new approach to reduce tauopathy.
EXPERIMENTAL PROCEDURES
Chemicals and Reagents
C646 was from Chembridge (San Diego, CA). C37 (inactive analog of C646)
was synthesized by David Meyers (Johns Hopkins University). We purchased
EX527 (Tocris Bioscience, Ellisville, MO), resveratrol (EMD Chemicals, Gibbs-
town, NJ), MG-132 (Sigma, St. Louis, MO), cycloheximide (Sigma), Ab42
peptide (rPeptide, Bogart, GA), and recombinant tau (rPeptide). Ab42 oligo-
mers were prepared as described (Chen et al., 2005).
Primary Antibodies
Two rabbit polyclonal anti-ac-tau antisera were generated against two
acetylated peptides of tau (Abgent, San Diego, CA). PHF1 antibody was
a kind gift of Peter Davis (Albert Einstein College ofMedicine). Other antibodies
were obtained and used at the indicated concentrations: Tau 5 (1:5000; Ab-
cam, Cambridge, MA), anti-p300 (1:500; Santa Cruz Biotechnology, Santa
Cruz, CA), anti-pCAF (E-8) (1:200; Santa Cruz Biotechnology), anti-HDAC6
(H-300) (1:200, Santa Cruz Biotechnology), anti-SIRT2 (1:1000, Abcam), anti-
GAPDH (1:10000; Sigma), anti-tubulin (1:10000; Sigma), anti-FLAG (1:2000;
Sigma), AT8 for p-tau (1:500; Thermo Fisher Scientific, Rockford, IL), anti-
Sir2 (1:2000; Millipore, Billerica, MA), and anti-HA (1:1000; Cell Signaling
Technology, Danvers, MA). Secondary antibodies used were as follows:
peroxidase-conjugated goat anti-rabbit and anti-mouse IgGs (1:2000; GE
Healthcare, Piscataway, NJ).
Expression Plasmids
For expression in HEK293T cells, cDNAs encoding hTauwt, hTau2KR (K174R,
K180R), hTau3KR (K163R, K174R, K180 R), p300, SIRT1, H363Y (SIRT1),
SIRT2, HDAC5, HDAC6, and HA-ubiquitin were cloned into pcDNA3.1 vector
(Invitrogen). For protein expression in bacteria, hTauwt cDNA was cloned into
pGEX4T-1 vector for GST-fusion protein expression. For expression in primary
neurons, cDNAs encoding hTauwt, hTau3KR, hTauP301, and cre recombi-
nase were cloned into lentiviral FUGW vectors.
Mice
All procedures involving animals were in compliance with the policies of the
Animal Care and Use Committee at the University of California, San Francisco.
PS19 mice were obtained from Jackson Laboratory (Bar Harbor, ME). The
hT-PAC-N line was a generous gift of Gerard D. Schellenberg (University of
Pennsylvania). SIRT null and SIRT1F/F mice were kindly provided by Fred Alt
(Harvard Medical School).
Cell Cultures and Transient Transfections
HEK293T cells and MEFs were grown at 37C in Dulbecco’s modified
Eagles medium supplemented with 10% fetal bovine serum, 100 U/mlNeuron 67, 953–966, September 23, 2010 ª2010 Elsevier Inc. 961
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Figure 6. Acetylation Slows Tau Turnover by Inhibiting Its Ubiquitination
(A) Inhibiting SIRT1 with EX527 (50 mM) elevated ac-tau and p-tau in rat primary neurons (DIV = 10). Shown on the left are representative western blots. p-tau was
detected with AT8. As shown on the right, levels of ac-tau/t-tau or p-tau/t-tau in vehicle-treated cells were set as 1. n = 6 independent treatments. ***p < 0.001;
*p < 0.05 (unpaired Student’s t test).
(B) Deletion of SIRT1 elevated AT8-positive p-tau in the brain. n = 3–4 mice/genotype. *p < 0.05 (SIRT1+/+ versus SIRT1/) (one-way ANOVA and Tukey-Kramer
post-hoc test).
(C and D) Tau3KR was more stable than wild-type tau in primary neurons. Cells were infected with Lenti-hTauwt or Lenti-hTau3KR and treated with CHX for
8–32 hr 4 days after infection (DIV = 9).
(C) Representative western blot of two experiments showing ac-tau, t-tau, and GAPDH.
(D) The turnover of t-tau was slower in cells expressing Tau3KR. t-tau/GAPDH levels in cells harvested at time 0 were set as 1. n = 3–5 from two experiments.
*p = 0.04 (8 h); p = 0.015 (24 h); ***p < 0.0001 (32 h) (unpaired t test for each time-point).
(E and F) SIRT1 inhibitor EX527 (1–50 mM) suppressed tau ubiquitination and elevated ac-tau in a dose-dependent manner. Blots are representative of three
experiments. See Figure S4, which shows that resveratrol-enhanced tau ubiquitination depended on SIRT1’s deacetylase activity.
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Figure 7. Tau Acetylation Is Elevated under
Pathological Conditions
(A) Tau acetylation was increased by low levels of
Ab oligomers in primary cortical neurons
(DIV = 11). n = 5 from 3 experiments. **p = 0.003
(one-way ANOVA and Tukey-Kramer posthoc
test).
(B) Tau acetylation was associated with familial
MAPT mutations in primary neurons (DIV = 13).
Ac-tau/t-tau levels in neurons infected with Lenti-
hTauwt were set as 1. n = 9 from three experi-
ments. *p = 0.013 (unpaired t test).
(C) RepresentativeWestern blots showing levels of
ac-tau, t-tau, and hyperphosphorylated tau in
human brains (Bm-22, superior temporal gyrus)
at different Braak stages (0–5).
(D) Ac-tau levels were elevated in patients with
mild (Braak stages 1–2) to moderate (Braak stages
3–4) levels of tau pathology. n = 8–18 cases/Braak
range. *p < 0.05; **p < 0.01, one-way ANOVA
Tukey-Kramer posthoc analyses. See Table S2
for the patient information. Values are means ±
SEM (A, B, D).
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Deacetylation of Tau Reduces Tauopathypenicillin, and 100 mg/ml streptomycin. For overexpression, transfections
were performed with Lipofectamine 2000 (Invitrogen). For siRNA oligonucle-
otide transfection, HEK293T cells were seeded at 1 3 105 cells/well on 12-
well culture plates. After 12 hr, cells were transfected with 10 nM ON-TAR-
GETplus SMARTpool siRNA (Thermo Scientific-Dharmacon, Chicago, IL)
with Lipofectamine RNAiMAX transfection reagent (Invitrogen), in accor-
dance with the manufacturer’s protocol. SIRT1 siRNA (L-094699-01),
SIRT2 siRNA (L-004826-00), HDAC6 siRNA (L-003499-00), p300 siRNA
(L-003486-00), and PCAF siRNA (L-005055-00) were used for targeting
specific cellular genes; siControl Non-Targeting siRNA#1 (Dharmacon)
was used as a negative control. Approximately 48 hr after siRNA transfec-
tion, plasmid pcDNA3.1-hTauwt was transfected into the same culture
plates. Cells were harvested 24 hr later for real-time RT-PCR or western
blot analyses.
Primary Neuronal Cultures and Lentiviral Infections
Primary cultures were established from cortices of Sprague-Dawley rat pups
(Charles River Laboratories) or SIRT1F/F mice on postnatal day 0 or 1. Purified
cells were plated at 160,000 cells/ml in Neurobasal medium supplemented(G–K) The SIRT1 inhibitor EX527 increases the half-life of tau in rat primary neurons (DIV = 8) in a dose-depe
0–8 hr in the presence or absence of EX527 (10–50 mM). Representative western blots of three experiments sho
in neurons with or without EX527 are shown.
(H and J) The turnover of t-tau (H) or ac-tau (J) was markedly slowed by treatment of EX527. Levels of t-tau
0 were set as 1. n = 3. **p < 0.01; ***p < 0.001 (two-way ANOVA, Berferroni post-hoc analyses, EX527-treated
ison of the half-life of ac-tau versus t-tau. Values represent means ± SEM (A–B, D, G, and I).
Neuron 67, 953–966, Sewith B27 (Invitrogen) on poly-ornithine-coated
plates. All treatments were performed at 7–13
DIV in Neurobasal medium supplemented with
N2 (Invitrogen) unless noted otherwise.
Lentivirus was generated, purified, and used for
infection as described (Chen et al., 2005). Re-
combinant lentivirus was produced by
cotransfection of the shuttle vector (FUGW), two
helper plasmids, delta8.9 packaging vector, and
VSV-G envelope vector into 293T cells and puri-
fied by ultracentrifugation. Viral titers weremeasured by p24 enzyme-linked immunosorbent assays at the Gladstone-
UCSF Laboratory of Clinical Virology.
Homogenization of Cells and Tissues and Western Blot Analyses
Cells or human or mouse brain tissues were lysed in RIPA buffer containing
protease inhibitor cocktail (Sigma), 1 mM phenylmethyl sulfonyl fluoride
(Sigma), phosphatase inhibitor cocktail (Roche), and HDAC inhibitors,
including 5 mM nicotinamide (Sigma) and 1 mM trichostatin A (Sigma). After
sonication, lysates from human or mouse brain tissues were centrifuged at
170,000 g at 4C for 15 min and at 18,000 g at 4C for 10 min. Supernatants
were collected and analyzed by Western blot. Bands in immunoblots were
visualized by enhanced chemiluminescence (Pierce) and quantified by
densitometry and Quantity One 4.0 software (Bio-Rad, Hercules, CA).
In Vitro Acetylation Assays
The reactions were performed as described (Pagans et al., 2005). In brief, 1 mg
of human recombinant tau, 2 nMof acetyl CoA (Sigma), and1ml of purifiedGST-
p300 in acetylation buffer (50 mM HEPES, pH 8.0, 10% glycerol, 1 mM dithio-
threitol (DTT), and 10 mM Na butyrate) were incubated for 30 min at 30C withndent manner. Neurons were treated with CHX for
wing the turnover of t-tau (G), ac-tau (I), or p-tau (K)
/tubulin or ac-tau/tubulin in cells harvested at time
versus vehicle-treated). See Figure S5 for compar-
ptember 23, 2010 ª2010 Elsevier Inc. 963
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Figure 8. Reducing Tau Acetylation Elimi-
nates p-Tau
(A) C646 (20 mM) eliminated ac-tau and AT8-posi-
tive p-tau within 2 hr in primary cortical neurons
(DIV = 9). Representative Western blot of two
experiments.
(B) C646 (20 mM) eliminated p-tau. Levels of p-tau/
GAPDH in non-treated cells were set as 1. n = 4.
***p < 0.0001 (unpaired t test).
(C) C646 (20 mM) eliminated AT8-positive p-tau in
primary neurons expressing hTauP301L (DIV =
12). Shown on the left is a representative western
blot of two experiments. As shown on the right,
Levels of p-tau/GAPDH in cells treated with control
compound (C37) were set as 1. n = 7. ***p = 0.0001
(unpaired t test).
(D) Hypothetical model of how tau acetylation may
contribute to tau-mediated neurodegeneration.
Dashed lines and factors in gray indicate pathways
not yet tested. Values are means ± SEM (B and C).
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Deacetylation of Tau Reduces Tauopathyconstant shaking. Reactions were stopped by an addition of 23 LDS sampling
buffer (Invitrogen), followed by SDS-PAGE and western blot analyses.
MALDI-TOF Analyses
Samples from in vitro acetylation reactions were run on SDS-polyacrylamide
gels and stained with Coomassie Blue. The band at 65 kDa was cut out
and sent to StanfordMass Spectrometry Laboratory for analyses. In-gel diges-
tion was done with Promega MS grade trypsin overnight. Before digestion, the
gel slices were cut into 1 mm 3 1 mm cubes, reduced with 5 mM DTT, and
alkylated with acrylamide. Peptides were extracted and dried down with
a speed-vac before reconstitution and analysis.
Nano reversed-phase HPLC was done with an Eksigent 2D nanoLC (Eksi-
gent, Dublin, CA) with buffer A consisting of 0.1% formic acid in water and
buffer B consisting of 0.1% formic acid in acetonitrile. A fused silica column
self packed with Duragel C18 (Peeke, Redwood City, CA) matrix was used
with a linear gradient from 5% B to 40% B over 80 min at a flow rate
of 450 nl/min. The nanoHPLC was interfaced with an Advion Nanomate964 Neuron 67, 953–966, September 23, 2010 ª2010 Elsevier Inc.(Ithaca, NY) for nano-electrospray ionization into
the mass spectrometer. The mass spectrometer
was a LCQ Deca XP Plus (Thermo Scientific),
which was set in data-dependent acquisition
mode for performing MS/MS on the top three
most intense ions with a dynamic exclusion setting
of two. The DTA files were extracted from the raw
data and systematically searched with Mascot.
At least two peptides with a probability >95%
were needed for the assignment of a protein.
In Vitro Deacetylation Assays
The reactions were modified from established
procedures (Pagans et al., 2005). HEK293T cells
were transfected with human FLAG-tagged
SIRT1 plasmid or mock plasmid with Lipofect-
amine 2000 (Invitrogen). After 24 hr, cells were
lysed in lysis buffer (50 mM Tris-HCl [pH 7.5],
0.5 mM EDTA, 0.5% NP-40, 150 mM NaCl, and
protease inhibitor cocktails). After centrifugation
at 13,000 rpm at 4C for 10 min, equal amounts
of supernatant proteins were immunoprecipitated
with FLAG M2 agarose beads (Sigma) for 3 hr at
4C. Immuoprecipitated beads were washed
twice in lysis buffer and once in deacetylation
buffer (50 mM Tris-HCl [pH 9.0], 4 mM MgCl2,and 0.2 mM DTT) and incubated with in vitro ac-tau in deacetylation
buffer at 30C for 3 hr with constant shaking. Reactions were stopped
by adding 2X LDS sampling buffer (Invitrogen) and analyzed by western
blotting.
In Vivo Ubiquitination Assays
Procedures were modified from a published study (Oh et al., 2009). HEK293T
cells were transfected with expression vectors encoding FLAG-tagged human
tau and HA-ubiquitin with or without Myc-SIRT1 (wild-type or H363Y mutant).
After 2 hr of incubation, cells were treated with EX527, resveratrol, or DMSO in
Dulbecco’smodified Eagle’smedium and incubated for 20 hr. MG-132 (20 mM)
was added and incubated for 4 hr. Cells were lysed in ubiquitination buffer
(20 mM Tris-HCl [pH 7.5], 0.1 mM EDTA, 0.2% Triton X-100, 150 mM NaCl,
and protease inhibitor cocktail). Supernatant proteins were immunoprecipi-
tated with FLAG M2 agarose beads (Sigma) for 3 hr at 4C. Reactions were
washed at least three times with ubiquitination buffer and analyzed by SDS-
PAGE and western blotting with anti-HA antibody (Cell Signaling Technology).
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Deacetylation of Tau Reduces TauopathyPurification of GST Fusion Proteins and Interaction Assays
Full-length cDNA encoding human tau was subcloned into pGEX-4T-1 bacte-
rial expression vector (Sigma) and transformed in the BL21 (DE3) strain. After
induction with 100 mM isopropyl b-D-1-thiogalactopyranoside, bacterial cells
were harvested and sonicated in phosphate-buffered saline with 1 mM
EDTA, 0.5%Triton X-100, and protease inhibitor cocktail (Sigma). GST-tagged
human tau or GST protein was purified with glutathione-agarose beads (Gen-
Script).
In GST pull-down assays, bead-bound forms of purified GST-tau were incu-
bated with lysates from HEK293T cells that were not transfected (for interac-
tion with endogenous SIRT1) or transfected with FLAG-tagged human
SIRT1. Beads were washed at least three times with lysis buffer containing
Triton X-100 or Nonidet-40 and analyzed by SDS-PAGE and western blotting
with anti-SIRT1 antibody (Millipore) or anti-FLAG antibody (Sigma).
In coimmunoprecipitation assays, HEK293T cells were transfected with
pcDNA3.1-hTau-FLAG. Triton X-100-solubilized lysates were incubated with
FLAG M2 agarose beads for 3 hr at 4C. Beads were washed at least three
times with lysis buffer containing Triton X-100 (0.5%) and analyzed by SDS-
PAGE and western blotting with anti-SIRT1 antibody (Millipore) or anti-FLAG
antibody (Sigma).Characterization of C646, a Selective p300 Inhibitor
C646was identified as one of the putative inhibitors of p300by a computational
docking screen (Bowers et al., 2010). A convenient spectrophotometric assay
was performed to validate it as a p300 inhibitor (Kim et al., 2000); this was
followed by a series of secondary assays. In the coupled spectrophotometric
assay, the acetyltransferase reaction product CoASH becomes a substrate for
alphaketoglutarate dehydrogenase, which converts NAD to NADH, resulting in
an increase of UV absorbance at 340 nm (Kim et al., 2000). A radioactive p300
HAT assay was subsequently performed for direct measurement of the IC50 of
C646. The specific inhibition of p300 versus other acetyltransferases by C646
was further examined. These acetyltransferases included serotonin N-acetyl-
transferase, and the HATs pCAF, GCN5, Rtt109, Sas, and MOZ .Data Analyses
Statistical analyses were conducted with Graphpad Prism. Differences among
multiple (R3) means with one variable were evaluated by one-way or two-way
ANOVA and the Tukey-Kramer or Bonferroni post-hoc test. Differences
between two means were assessed with the paired or unpaired two-tailed t
test. p < 0.05 was considered significant.SUPPLEMENTAL INFORMATION
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